BFRI RSI Chart
Last 7 days
-15.1%
Last 30 days
-37.4%
Last 90 days
42.7%
Trailing 12 Months
-88.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 33.3M | 0 | 0 | 0 |
2023 | 27.7M | 29.0M | 33.6M | 34.1M |
2022 | 29.1M | 27.7M | 27.7M | 28.7M |
2021 | 20.2M | 21.5M | 22.8M | 24.1M |
2020 | 0 | 0 | 22.5M | 18.8M |
2019 | 0 | 0 | 0 | 26.2M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 18, 2023 | monaco erica l. | acquired | - | - | 76,336 | chief executive officer |
May 18, 2023 | luebbert hermann | acquired | - | - | 95,420 | executive chairman |
Aug 22, 2022 | luebbert hermann | acquired | - | - | 113,379 | executive chairman |
Jul 01, 2022 | monaco erica l. | acquired | - | - | 56,689 | chief executive officer |
Which funds bought or sold BFRI recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | MORGAN STANLEY | sold off | -100 | -554 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -1.00 | - | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | sold off | -100 | -30.00 | - | -% |
May 15, 2024 | Tower Research Capital LLC (TRC) | reduced | -39.96 | -5,855 | 2,934 | -% |
May 15, 2024 | Royal Bank of Canada | unchanged | - | - | - | -% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 374 | 374 | -% |
May 14, 2024 | AIGH Capital Management LLC | new | - | 766,203 | 766,203 | 0.23% |
May 14, 2024 | SCOTIA CAPITAL INC. | new | - | 61,600 | 61,600 | -% |
May 13, 2024 | RENAISSANCE TECHNOLOGIES LLC | new | - | 16,000 | 16,000 | -% |
May 13, 2024 | XTX Topco Ltd | new | - | 18,765 | 18,765 | -% |
Unveiling Biofrontera Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Biofrontera Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 372.2B | 85.6B | 9.67 | 4.35 | ||||
MRK | 332.3B | 61.4B | 144.1 | 5.41 | ||||
AMGN | 167.7B | 29.5B | 44.55 | 5.68 | ||||
PFE | 162.3B | 57.8B | 129.52 | 2.81 | ||||
GILD | 84.4B | 27.4B | 174.21 | 3.07 | ||||
TEVA | 18.4B | 16.0B | -37.29 | 1.15 | ||||
MID-CAP | ||||||||
ALKS | 4.1B | 1.7B | 9.41 | 2.37 | ||||
PRGO | 4.1B | 4.6B | -528.11 | 0.89 | ||||
BHC | 2.5B | 9.0B | -5.45 | 0.28 | ||||
AMPH | 2.1B | 676.2M | 13.75 | 3.14 | ||||
SMALL-CAP | ||||||||
TLRY | 1.5B | 743.2M | -4.35 | 2.06 | ||||
TXMD | 25.8M | 1.3M | -3.49 | 19.84 | ||||
ACRX | 18.4M | 89.6M | -1.29 | 0.19 | ||||
AGRX | 2.5M | 21.5M | -0.32 | 0.12 | ||||
ACOR | 633.5K | 115.7M | 0 | 0.01 |
Biofrontera Inc. News
Income Statement (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Revenue | -25.3% | 7,912,000 | 10,595,000 | 8,896,000 | 5,848,000 | 8,733,000 | 10,144,000 | 4,322,000 | 4,457,000 | 9,751,000 | 9,167,500 | 4,334,000 | 5,855,000 | 4,744,000 | 3,998,000 | 3,252,000 | - |
Operating Expenses | -7.5% | 13,379,000 | 14,460,500 | 13,516,000 | 14,547,000 | 14,225,000 | 15,764,000 | 7,961,000 | 10,669,000 | 12,861,000 | 11,048,000 | 20,439,000 | 9,542,000 | 8,272,000 | - | 5,596,000 | - |
S&GA Expenses | -100.0% | - | 9,100,500 | 8,619,000 | 11,456,000 | 9,800,000 | 10,087,000 | 7,765,000 | 9,669,000 | 7,616,000 | 9,106,000 | 17,090,000 | 5,552,000 | 4,758,000 | - | 4,191,000 | - |
R&D Expenses | -48.5% | 17,000 | 33,000 | 33,000 | 11,000 | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA Margin | -24.1% | -0.75 | -0.60 | -0.79 | -0.78 | -0.50 | -0.02 | -0.45 | -0.93 | -0.99 | -1.57 | -0.60 | -0.64 | -0.68 | -0.73 | - | - |
Interest Expenses | -563.7% | -1,407,000 | -212,000 | -142,000 | -79,000 | -35,000 | -35,000 | -89,000 | -38,000 | -33,000 | -89,000 | -86,000 | -85,000 | -84,000 | - | -744,000 | - |
Income Taxes | 116.7% | 1,000 | -6,000 | 1,000 | 14,000 | 5,000 | 1,000 | 1,000 | - | 30,000 | 5,000 | 6,000 | 44,000 | 1,000 | - | 61,000 | - |
Earnings Before Taxes | -396.5% | -10,436,000 | 3,520,000 | -6,341,000 | -9,823,000 | -7,473,000 | -2,784,000 | -2,565,000 | -850,000 | 5,591,000 | -14,500,500 | -16,006,000 | -3,617,000 | -3,533,000 | - | -2,924,000 | - |
EBT Margin | -17.6% | -0.69 | -0.59 | -0.79 | -0.78 | -0.49 | -0.02 | -0.44 | -0.93 | -0.98 | -1.56 | -0.48 | -0.51 | -0.54 | -0.58 | - | - |
Net Income | -396.0% | -10,437,000 | 3,526,000 | -6,342,000 | -9,837,000 | -7,478,000 | -2,785,000 | -2,566,000 | -850,000 | 5,561,000 | -14,505,500 | -16,012,000 | -3,661,000 | -3,534,000 | - | -2,985,000 | - |
Net Income Margin | -17.5% | -0.69 | -0.59 | -0.79 | -0.78 | -0.49 | -0.02 | -0.45 | -0.93 | -0.98 | -1.56 | -0.48 | -0.51 | -0.54 | -0.58 | - | - |
Free Cashflow | 62.0% | -3,382,000 | -8,891,000 | -2,000,000 | -10,300,000 | -3,714,000 | -8,300,000 | -5,914,000 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q4 |
Assets | -12.0% | 24,575 | 27,932 | 34,104 | 36,905 | 41,965 | 50,884 | 55,059 | 53,626 | 49,202 | 53,219 | 15,354 | 18,282 | 21,210 | 24,138 | 28,752 |
Current Assets | -12.7% | 20,155 | 23,075 | 29,611 | 32,296 | 37,223 | 43,140 | 48,493 | 46,981 | 42,531 | 46,421 | 10,137 | - | - | 19,576 | 23,468 |
Cash Equivalents | 184.2% | 3,817 | 1,343 | 3,422 | 4,453 | 13,505 | 17,208 | 27,518 | 31,913 | 22,428 | 24,545 | 1,716 | - | - | 8,080 | 7,302 |
Inventory | -36.7% | 6,905 | 10,908 | 16,068 | 14,785 | 6,670 | 7,168 | 12,087 | 8,808 | 4,872 | 4,458 | 5,439 | - | - | 7,091 | 10,480 |
Net PPE | -10.4% | 120 | 134 | 154 | 175 | 197 | 204 | 224 | 248 | 245 | 267 | 289 | - | - | 370 | 503 |
Liabilities | 14.2% | 26,421 | 23,139 | 33,066 | 29,732 | 25,214 | 27,006 | 32,464 | 36,393 | 31,786 | 41,881 | 32,734 | 27,926 | 23,118 | 18,310 | 58,931 |
Current Liabilities | -22.4% | 14,036 | 18,088 | 29,124 | 25,352 | 20,450 | 20,894 | 17,143 | 14,876 | 12,359 | 13,836 | 11,291 | - | - | 4,420 | 11,742 |
Short Term Borrowings | -39.7% | 2,355 | 3,904 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -213.0% | -5,416 | 4,793 | 1,038 | 7,173 | 16,751 | 23,878 | 22,595 | 17,233 | 17,416 | 11,338 | - | - | 2,294 | 5,828 | - |
Retained Earnings | -10.4% | -110,087 | -99,700 | -103,176 | -96,800 | -86,997 | -79,519 | -76,734 | -74,200 | -73,300 | -78,879 | -64,400 | - | - | -41,166 | -30,179 |
Additional Paid-In Capital | 0.2% | 104,666 | 104,441 | 104,213 | 103,980 | 103,721 | 103,396 | 99,306 | 91,382 | 90,717 | 90,216 | 46,986 | - | - | 46,986 | - |
Shares Outstanding | 235.4% | 5,089 | 1,518 | 1,368 | 1,368 | 1,335 | 1,335 | 978 | 898 | 855 | 855 | 400 | 400 | 400 | 400 | - |
Float | - | - | - | - | 14,200 | - | - | - | 35,400 | 36,800 | - | - | - | - | - | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2019Q4 |
Cashflow From Operations | 62.6% | -3,325 | -8,900 | -2,000 | -10,300 | -3,700 | -8,299 | -5,913 | 113 | -2,100 | -20,990 | -1,225 | -1,100 | -3,400 | - | - | - |
Share Based Compensation | 0% | 228 | 228 | 207 | 259 | 351 | 383 | 401 | 551 | 517 | - | - | - | - | - | - | - |
Cashflow From Investing | -100.0% | - | 73.00 | 382 | 178 | -14.00 | -2,086 | -3,034 | -31.00 | -5.00 | -9.00 | 1.00 | - | - | - | - | - |
Cashflow From Financing | -13.6% | 5,799 | 6,714 | 591 | 1,106 | - | - | 4,630 | - | - | 43,829 | -121 | - | - | - | - | - |
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Defined Benefit Plan Disclosure [Line Items] | ||
Products revenues, net | $ 7,901 | $ 8,715 |
Revenues, related party | 11 | 18 |
Total revenues, net | 7,912 | 8,733 |
Operating expenses | ||
Selling, general and administrative, related party | (4) | 27 |
Research and development | 17 | |
Change in fair value of contingent consideration | (200) | |
Total operating expenses | 13,379 | 14,225 |
Loss from operations | (5,467) | (5,492) |
Other income (expense) | ||
Change in fair value of warrant liabilities | (3,429) | 1,028 |
Change in fair value of investment, related party | 3 | (2,941) |
Loss on debt extinguishment | (316) | |
Interest expense, net | (1,407) | (35) |
Other income (expense), net | 180 | (33) |
Total other income (expense) | (4,969) | (1,981) |
Loss before income taxes | (10,436) | (7,473) |
Income tax expense | 1 | 5 |
Net loss | (10,437) | (7,478) |
Related Party [Member] | ||
Operating expenses | ||
Cost of revenues | 3,946 | 4,547 |
Nonrelated Party [Member] | ||
Operating expenses | ||
Cost of revenues | 170 | 51 |
Selling, general and administrative | $ 9,250 | $ 9,800 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 3,817 | $ 1,343 |
Accounts receivable, net | 3,520 | 5,162 |
Inventories, net | 6,905 | 10,908 |
Prepaid expenses and other current assets | 560 | 425 |
Total current assets | 20,155 | 23,075 |
Property and equipment, net | 120 | 134 |
Operating lease right-of-use assets | 1,416 | 1,612 |
Intangible asset, net | 2,556 | 2,629 |
Other assets | 328 | 482 |
Total assets | 24,575 | 27,932 |
Current liabilities: | ||
Operating lease liabilities | 690 | 691 |
Accrued expenses and other current liabilities | 4,230 | 4,487 |
Short term debt | 2,355 | 3,904 |
Total current liabilities | 14,036 | 18,088 |
Long-term liabilities: | ||
Warrant liabilities | 11,731 | 4,210 |
Operating lease liabilities, non-current | 621 | 804 |
Other liabilities | 33 | 37 |
Total liabilities | 26,421 | 23,139 |
Commitments and contingencies (Note 17) | ||
Stockholders’ equity: | ||
Preferred Stock, $0.001 par value, 19,978,828 shares authorized, zero shares issued and outstanding as of March 31, 2024 and December 31, 2023 | ||
Common Stock, $0.001 par value, 15,000,000 shares authorized; 5,089,413 and 1,517,628 shares issued and outstanding as of March 31, 2024 and December 31, 2023 | 5 | 2 |
Additional paid-in capital | 104,666 | 104,441 |
Accumulated deficit | (110,087) | (99,650) |
Total stockholders’ equity | (5,416) | 4,793 |
Total liabilities, mezzanine equity and stockholders’ equity | 24,575 | 27,932 |
Series B1 Preferred Stock [Member] | ||
Mezzanine equity: | ||
Series B-1 Convertible Preferred Stock, $0.001 par value, 6,586 share authorized, 4,806 and zero shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 3,570 | |
Related Party [Member] | ||
Current assets: | ||
Investment, related party | 23 | 78 |
Other receivables, related party | 171 | |
Other assets, related party | 5,159 | 5,159 |
Current liabilities: | ||
Accounts payable, related parties | 4,044 | 5,698 |
Nonrelated Party [Member] | ||
Current liabilities: | ||
Accounts payable, related parties | $ 2,717 | $ 3,308 |
 | Dr. Hermann Luebbert Ph.D. |
---|---|
 | biofrontera-us.com |
 | Pharmaceuticals |
 | 81 |